Stockscreener 앱 받기
70.05
0.75%
1.07
전일 마감가:
$68.98
열려 있는:
$68.01
하루 거래량:
4,080
Relative Volume:
0.08
시가총액:
$2.20B
수익:
-
순이익/손실:
$-32.61M
주가수익비율:
-59.66
EPS:
-1.1742
순현금흐름:
-
1주 성능:
-0.54%
1개월 성능:
+9.76%
6개월 성능:
+24.11%
1년 성능:
+39.28%
1일 변동 폭
$68.01
$70.26
1주일 범위
$68.01
$74.49
52주 변동 폭
$43.70
$86.53
Belite Bio Inc Adr Stock (BLTE) Company Profile
BLTE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
69.02 | 2.35B | 0 | -32.61M | 0 | -1.1742 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.53 | 101.51B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
576.87 | 59.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
440.54 | 56.69B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
648.31 | 39.57B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
314.60 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-14 | 개시 | Maxim Group | Buy |
| 2023-07-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-07-26 | 개시 | SVB Securities | Outperform |
| 2022-08-01 | 개시 | H.C. Wainwright | Buy |
| 2022-07-01 | 개시 | The Benchmark Company | Buy |
Belite Bio Inc Adr 주식(BLTE)의 최신 뉴스
Q3 EPS Estimates for Belite Bio Lowered by Leerink Partnrs - Defense World
Multi factor analysis applied to Belite Bio Inc Depositary ReceiptMarket Growth Review & Fast Exit and Entry Trade Guides - Newser
Belite Bio FY2029 EPS Forecast Reduced by Leerink Partnrs - Defense World
Belite Bio’s Tinlarebant: A Promising Investment with Breakthrough Potential for Stargardt Disease - TipRanks
Benchmark Co. Reiterates Buy Rating on Belite Bio, Sets $80 Price Target - AInvest
Belite Bio’s Earnings Call: Progress Amid Challenges - TipRanks
Benchmark reiterates Buy rating on Belite Bio stock, maintains $80 price target - Investing.com Nigeria
Promising Clinical Trials and Regulatory Advancements Support Buy Rating for Belite Bio, Inc. - TipRanks
Belite Bio targets NDA submission for Tinlarebant in first half of 2026 amid strong cash runway and Phase III progress - MSN
Belite Bio Advances Retinal Disease Treatments Amid Financial Growth - TipRanks
Belite Bio's Tinlarebant: A Groundbreaking Therapy on the Cusp of Approval in Stargardt Disease and Geographic Atrophy - AInvest
Belite Bio Aims for NDA Submission by H1 2026 with Robust Cash Runway and Advancing Phase III Trials - AInvest
Belite Bio Q2 2025 presentation: expenses rise as clinical trials advance - Investing.com Canada
Earnings call transcript: Belite Bio Q2 2025 beats EPS expectations despite losses - Investing.com
Belite Bio Q2 2025 Earnings Call Transcript - MarketBeat
Belite Bio Shares Drop Despite Clinical Milestones - TipRanks
Belite Bio reports Q2 EPS (50c), consensus (42c) - TipRanks
Belite Bio Announces Q2 2025 Financial Results and Key Clinical Milestones - TipRanks
Why Belite Bio's Widening Losses Signal a High-Probability Path to Market Leadership in Retinal Therapies - AInvest
Belite Bio's Tinlarebant: A First-in-Class Therapeutic Candidate with Dual-Indication Potential in High-Value Retinal Diseases - AInvest
Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - The Globe and Mail
Belite Bio, Inc. ADR: Stock Movement Explained - TipRanks
Belite Bio Announces $15 Million Direct Offering - TipRanks
Belite Bio raises $15 million in registered direct offering - Investing.com
Belite Bio Raises $15M in Strategic Financing with Potential for Additional $15M from Warrants - Stock Titan
Belite Bio Experts Join Pivotal Retinal Disease Panel at Major Ophthalmology Conference - Stock Titan
New Strong Sell Stocks for August 4th - sharewise.com
Belite Bio Announces Q2 Earnings Call: Latest Updates on Novel Retinal Disease Therapeutics Pipeline - Stock Titan
Belite Bio Reports Q2 Financial Results, Business Update Webcast Scheduled. - AInvest
New Strong Sell Stocks for July 22nd - The Globe and Mail
Belite Bio (BLTE) Expected to Announce Earnings on Friday - Defense World
Leading vs lagging indicators on Belite Bio Inc Depositary Receipt performanceDay Trading Plan with Entry Risk Management - Newser
A Look At The Intrinsic Value Of Belite Bio, Inc (NASDAQ:BLTE) - uk.finance.yahoo.com
Belite Bio Executives Share Latest Retinal Disease Breakthroughs at BTIG Biotech Conference - Stock Titan
Belite Bio to Participate in BTIG Virtual Biotechnology Conference - AInvest
New Strong Sell Stocks For July 22nd - Barchart.com
What analysts say about Belite Bio Inc Depositary Receipt stockConsistent wealth multiplication - jammulinksnews.com
Belite Bio concludes enrollment for phase 3 GA trial on oral tinlarebant - Eyes On Eyecare
Stargardt Disease Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Nanoscope Therapeutics, Belite Bio, Biophytis, reVision Therapeutics, Inc - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Solid Biosciences (SLDB) and Belite Bio, Inc. ADR (BLTE) - The Globe and Mail
Q2 EPS Estimates for Belite Bio Decreased by Leerink Partnrs - Defense World
Ouster Announces Date for Second Quarter 2025 Earnings Call - The Globe and Mail
Belite Bio, Inc.’s Tinlarebant: Promising Treatment for Stargardt Disease with Significant Market Potential - TipRanks
Phase 3 PHOENIX trial for oral GA treatment completes enrollment - Modern Retina
Belite Bio stock maintains Buy rating at H.C. Wainwright on trial progress - Investing.com India
Positive Buy Rating for Belite Bio Driven by Phase 3 PHOENIX Trial Milestone and Regulatory Designations - TipRanks
Belite Bio Completes Enrollment for Phase 3 PHOENIX Trial on Tinlarebant - TipRanks
Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy - The Manila Times
Analysts Issue Forecasts for Belite Bio FY2026 Earnings - Defense World
Reviewing Belite Bio (NASDAQ:BLTE) & ZyVersa Therapeutics (NASDAQ:ZVSA) - Defense World
Bank of America Corp DE Acquires 4,891 Shares of Belite Bio, Inc (NASDAQ:BLTE) - Defense World
Belite Bio Inc Adr (BLTE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.37%
0.57%
자본화:
|
볼륨(24시간):